I think we're literally only days or weeks away from the 67% milestone - Interim Ph1b Patient Data.
Which is why Leslie mentioned that 2/3 figure in the Small Caps presentation nearly 3 weeks ago (can't believe it's already that long..).
If the data is as 'beautiful' as she said, & I believe it will be (she was confident HER-Vaxx is superior to Herceptin, the EPD results back in Feb strengthened this view & also no safety issues), we should be looking at re-rating to at least $150m MC (SP of 5.3c).
Current SP of 2.8c is really really cheap considering how close we are to that next milestone. We should really be hovering around mid 3c. This reminded me of the time the SP dipped around 1.4-1.5c due to impatient market just days prior to the 3 significant announcement in Feb.
IMO those with enough patience will be rewarded.
Have a great weekend all!
Add to My Watchlist
What is My Watchlist?
